U.S. markets closed

AnaptysBio, Inc. (AN6.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
23.24-0.07 (-0.30%)
At close: 7:55PM CET

AnaptysBio, Inc.

10421 Pacific Center Court
Suite 200
San Diego, CA 92121
United States
858 362 6295
http://www.anaptysbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees94

Key Executives

NameTitlePayExercisedYear Born
Mr. Hamza SuriaPres, CEO & Director573.54k3.57M1976
Mr. Eric J. LoumeauCOO & Gen. Counsel480.76kN/A1963
Mr. Dennis M. MulroyChief Financial OfficerN/AN/A1955
Ms. Beth MuellerSr. VP of HRN/AN/AN/A
Dr. Margaret MarinoSr. VP of Project ManagementN/AN/AN/A
Dr. Paul F. LizzulChief Medical OfficerN/AN/A1975
Mr. David McKeonVP & ControllerN/AN/A1972
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis and palmoplantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd.; collaboration with Celgene Corporation; and immuno-oncology collaboration agreement with GlaxoSmithKline plc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.

Corporate Governance

AnaptysBio, Inc.’s ISS Governance QualityScore as of December 2, 2020 is 9. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.